Using human-relevant, translational in vitro models is widely considered to reduce attrition during drug discovery and development. Despite this, the adoption of models based on microphysiological systems — organs-on-chips or organoids — by pharma companies is moderate at best, and realizing the full potential of these models will need greater collaboration between stakeholders.

中文翻译：

---

微生理系统的机遇与挑战：制药最终用户的观点

人们广泛认为，使用与人类相关的体外翻译模型可减少药物发现和开发过程中的磨损。尽管如此，制药公司采用基于微生理系统（芯片上的器官或类器官）的模型充其量是适度的，要实现这些模型的全部潜力，就需要利益相关者之间进行更大的协作。